Dr. Reddy's Laboratories Limited has informed the Exchange about Dividend Updates

Revenue growth above 20%EBITDA margin compressionResults restatedRelated-party transactionsResults View source PDF Explain this filing

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.1%Reaction day

₹1158.09

prior close

₹1155.90

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)+3.9%-0.8% vs market

Pharmaceuticals peers, median of 148sector+2.8%+0.3% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty 100 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.7

10m

+0.3

15m

+0.2

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.1+3.9-0.8+2.8+0.3

Next day

+4.3+2.7+1.7+4.2+0.1

+5.4+3.1+2.3+5.3+0.1

+6.3+4.6+1.6+5.5+0.8

+6.1+4.7+1.4+6.3-0.2

+5.0+4.6+0.4+7.2-2.2

+5.8+4.0+1.8+6.4-0.7

15d

+7.9+3.7+4.2+7.1+0.8

+17.1+4.4+12.7+8.7+8.4

+8.1+5.3+2.8+11.2-3.1

+5.2+2.7+2.6+6.0-0.7

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr. Reddy's announced audited consolidated results for Q4 and FY25 (year ended March 31, 2025). Q4FY25 revenue rose 20% year-on-year to Rs. 85,060 million, driven by the recently acquired Nicotine Replacement Therapy (NRT) business from Haleon and growth in Global Generics. Full-year revenue grew 17% to Rs. 325,535 million, but profit after tax attributable to shareholders rose only 2% to Rs. 56,544 million due to higher costs and impairments. Q4 profit after tax jumped 22% year-on-year to Rs. 15,939 million. The board recommended a final dividend of Rs. 8 per equity share (face value Rs. 1) and re-appointed G V Prasad as Co-Chairman & Managing Director for five years from January 2026. Statutory auditors issued an 'Unmodified Opinion' (clean audit) on the financials.

Likely market impact

Strong Q4 revenue growth and clean audit opinion are positives for shareholders, but muted full-year PAT growth (just 2%) and gross margin compression (down 300 bps YoY in Q4) suggest margin pressures from price erosion and acquisition costs. The Rs. 8 dividend continues the company's regular payout, and the NRT acquisition is meaningfully boosting top-line growth in Europe.